---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000025"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:56:15.274317+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q1 revenue up 35% to $265M; raises FY25 guidance, announces $250M buyback

## Summary
- Q1 revenue $264.9M (+35% YoY); GAAP EPS $0.93 (+55%); non-GAAP EPS $1.11 (+41%).
- Raised 2025 guidance: revenue $1.2-1.28B (prev $1.15-1.225B), adj. EBITDA $790-840M, non-GAAP EPS $5.30-5.70.
- Announced new $250M share repurchase; completed first $250M ASR in March 2025.
- Filed patent infringement lawsuit against Merck over MDASE for subcutaneous Keytruda.

## SEC filing metadata
- accession: 0001159036-25-000025
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/0001159036-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/halo-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000025
- JSON: https://secwatch.observer/filing/0001159036-25-000025.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.